Seeking Alpha

Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of...

Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of the drug developer's previously announced positive results for the Phase III trial of oritavancin. The firm now sees it as a takeout candidate and reiterates an Outperform. Separately, JPMorgan also ups the shares to Overweight.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|